Phase II trial of 5 day continuous intravenous infusion of 6-thioguanine in patients with recurrent and metastatic squamous cell carcinoma of the head and neck.
Fifteen patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck received a 5 day continuous I.V. infusion of 6-thioguanine repeated every five weeks. Dose limiting toxicity was primarily hematological with grade III/IV leucopenia and thrombocytopenia seen in seven patients. Nausea and vomiting was moderate and well controlled with antiemetics. No complete or partial responses were observed, with a median time to progression of 58 days and a median survival of 227+ days for the entire group. Based on these results we do not recommend I.V. 6-thioguanine for the treatment of this disease.
Kruter
F
F
Department of Medicine, University of Maryland Cancer Center, University of Maryland School of Medicine.
Eisenberger
M
M
Sinibaldi
V
V
Engstrom
C
C
Jacobs
M
M
Abrams
J
J
Belani
C
C
Gray
W
W
Krasnow
S
S
D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000556:secondary; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D013866:Thioguanine / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
D013866:Thioguanine